Article

FDA finalizes donor eligibility criteria for human tissues, cells

The FDA has established donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable diseases during transplantation.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Robert Jansen, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
2 experts in this video
2 experts in this video
Related Content
Biopsy grade alone may underestimate risk in GG1 prostate cancer
August 1st 2025

Biopsy grade alone may underestimate risk in GG1 prostate cancer

Hannah Clarke
Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.
Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD
August 1st 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD
Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.
SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology
August 1st 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke
Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
August 1st 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Trial launches of ABO-101 for primary hyperoxaluria type 1
August 1st 2025

Trial launches of ABO-101 for primary hyperoxaluria type 1

Hannah Clarke
The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.
Enzalutamide shows improved relative efficacy over darolutamide in mHSPC
August 1st 2025

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Hannah Clarke
Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.
© 2025 MJH Life Sciences

All rights reserved.